BS, Kansas State University, Manhattan, KS

Mentor: Dawn Quelle, PhD

Comprehensive Exam: RABL6A, a novel oncogene and regulator of immunomodulation

The primary research goal of the Quelle lab is to develop new therapies for rare cancers. My thesis work is aimed at understanding how Malignant Peripheral Nerve Sheath Tumors, a type of sarcoma, respond to targeted therapy and immunotherapy. Many sarcomas are inherently resistant to immunotherapy so understanding factors contributing to response and resistance is a massive barrier to moving immunotherapy to the sarcoma world.

Publications:

1. Kohlmeyer JL, Kaemmer CA, Lingo JJ, Voigt E, Leidinger MR, McGivney GR, Scherer A, Koppenhafer SL, Gordon DJ, Breheny P, Meyerholz DK, Tanas MR, Dodd RD, Quelle DE. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. Neurooncol Adv. 2022 Apr 9;4(1):vdac047. doi: 10.1093/noajnl/vdac047. PMID: 35571990; PMCID: PMC9092646.

2.  Kohlmeyer JL*, Lingo JJ*, Kaemmer CA, Scherer A, Warrier A, Voigt E, Raygoza Garay JA, McGivney GR, Brockman QR, Tang A, Calizo A, Pollard K, Zhang X, Hirbe AC, Pratilas CA, Leidinger M, Breheny P, Chimenti MS, Sieren JC, Monga V, Tanas MR, Meyerholz DK, Darbro BW, Dodd RD, Quelle DE. CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. Clin Cancer Res. 2023 Sep 1;29(17):3484-3497. doi: 10.1158/1078-0432.CCR-23-0749. PMID: 37410426; PMCID: PMC10528807. * indicates co-first authorship

Awards:

• Pharmacological and Pharmaceutical Sciences Annual Retreat Best Oral Presentation, 2022

• Pharmacological and Pharmaceutical Sciences Annual Retreat Best Poster, 2023

• Fellowship Appointment, Pharmacological Sciences T32, 2021

• Fellowship Appointment, NRSA F31 Diversity, 2023

ORCiD: 0000-0002-4089-9052

LinkedIn: joshua-lingo-3096a91a5

Cancer Biology PhD Program